Norsalsolinol information

Norsalsolinol
Names
	Preferred IUPAC name 1,2,3,4-Tetrahydroisoquinoline-6,7-diol
	Other names 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
Identifiers
CAS Number	34827-33-3 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:173739;
ChemSpider	33891 ;
PubChem CID	36937;
UNII	9SPO03ZH41 ;
CompTox Dashboard (EPA)	DTXSID90188366 ;
	InChI InChI=1S/C9H11NO2/c11-8-3-6-1-2-10-5-7(6)4-9(8)12/h3-4,10-12H,1-2,5H2 Key: MBFUSGLXKQWVDW-UHFFFAOYSA-N ; InChI=1/C9H11NO2/c11-8-3-6-1-2-10-5-7(6)4-9(8)12/h3-4,10-12H,1-2,5H2 Key: MBFUSGLXKQWVDW-UHFFFAOYAF;
	SMILES C1CNCC2=CC(=C(C=C21)O)O;
Properties
Chemical formula	C9H11NO2
Molar mass	165.189 g/mol
Hazards
	Occupational safety and health (OHS/OSH):
Main hazards	Neurotoxin
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Norsalsolinol is a chemical compound that is produced naturally in the body through metabolism of dopamine.^[1] It has been shown to be a selective dopaminergic neurotoxin,^[2]^[3]^[4] and has been suggested as a possible cause of neurodegenerative conditions such as Parkinson's disease and the brain damage associated with alcoholism,^[5]^[6] although evidence for a causal relationship is unclear.^[7]^[8]^[9]

(R)-Salsolinol which has been shown to be a product of ethanol metabolism, stereospecifically induces behavioral sensitization and leads to excessive alcohol intake in rats^[10]

^ Maruyama W, Takahashi T, Minami M, Takahashi A, Dostert P, Nagatsu T, Naoi M (1993). "Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines". Advances in Neurology. 60: 224–30. PMID 8093579.
^ Maruyama Y, Suzuki Y, Kazusaka A, Fujita S (May 2001). "Norsalsolinol uptake into secretory vesicles via vesicular monoamine transporter and its secretion by membrane depolarization or purinoceptor stimulation in PC12 cells". The Journal of Veterinary Medical Science. 63 (5): 493–7. doi:10.1292/jvms.63.493. PMID 11411492.
^ Maruyama Y, Suzuki Y, Kazusaka A, Fujita S (June 2001). "Uptake of the dopaminergic neurotoxin, norsalsolinol, into PC12 cells via dopamine transporter". Archives of Toxicology. 75 (4): 209–13. doi:10.1007/s002040000202. PMID 11482518. S2CID 38150947.
^ Kobayashi H, Fukuhara K, Tada-Oikawa S, Yada Y, Hiraku Y, Murata M, Oikawa S (January 2009). "The mechanisms of oxidative DNA damage and apoptosis induced by norsalsolinol, an endogenous tetrahydroisoquinoline derivative associated with Parkinson's disease". Journal of Neurochemistry. 108 (2): 397–407. doi:10.1111/j.1471-4159.2008.05774.x. PMID 19012744.
^ Dostert P, Strolin Benedetti M, Della Vedova F, Allievi C, La Croix R, Dordain G, Vernay D, Durif F (1993). "Dopamine-derived tetrahydroisoquinolines and Parkinson's disease". Advances in Neurology. 60: 218–23. PMID 8420138.
^ Musshoff F, Daldrup T, Bonte W, Leitner A, Lesch OM (October 1997). "Salsolinol and norsalsolinol in human urine samples". Pharmacology Biochemistry and Behavior. 58 (2): 545–50. doi:10.1016/S0091-3057(97)00251-7. PMID 9300617. S2CID 76761.
^ Musshoff F, Lachenmeier DW, Kroener L, Schmidt P, Dettmeyer R, Madea B (July 2003). "Simultaneous gas chromatographic-mass spectrometric determination of dopamine, norsalsolinol and salsolinol enantiomers in brain samples of a large human collective". Cellular and Molecular Biology (Noisy-le-Grand, France). 49 (5): 837–49. PMID 14528920.
^ Scholz J, Klingemann I, Moser A (April 2004). "Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 75 (4): 634–6. doi:10.1136/jnnp.2003.010769. PMC 1739023. PMID 15026514.
^ Musshoff F, Lachenmeier DW, Schmidt P, Dettmeyer R, Madea B (January 2005). "Systematic regional study of dopamine, norsalsolinol, and (R/S)-salsolinol levels in human brain areas of alcoholics". Alcoholism: Clinical and Experimental Research. 29 (1): 46–52. doi:10.1097/01.ALC.0000150011.81102.C2. PMID 15654290.
^ "(R)-Salsolinol, a product of ethanol metabolism, stereospecifically induces behavioral sensitization and leads to excessive alcohol intake. | PubFacts.com". www.pubfacts.com. Retrieved 2017-10-02.

[pmid8093579-1] Maruyama W, Takahashi T, Minami M, Takahashi A, Dostert P, Nagatsu T, Naoi M (1993). "Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines". Advances in Neurology. 60: 224–30. PMID 8093579.

[pmid11411492-2] Maruyama Y, Suzuki Y, Kazusaka A, Fujita S (May 2001). "Norsalsolinol uptake into secretory vesicles via vesicular monoamine transporter and its secretion by membrane depolarization or purinoceptor stimulation in PC12 cells". The Journal of Veterinary Medical Science. 63 (5): 493–7. doi:10.1292/jvms.63.493. PMID 11411492.

[pmid11482518-3] Maruyama Y, Suzuki Y, Kazusaka A, Fujita S (June 2001). "Uptake of the dopaminergic neurotoxin, norsalsolinol, into PC12 cells via dopamine transporter". Archives of Toxicology. 75 (4): 209–13. doi:10.1007/s002040000202. PMID 11482518. S2CID 38150947.

[pmid19012744-4] Kobayashi H, Fukuhara K, Tada-Oikawa S, Yada Y, Hiraku Y, Murata M, Oikawa S (January 2009). "The mechanisms of oxidative DNA damage and apoptosis induced by norsalsolinol, an endogenous tetrahydroisoquinoline derivative associated with Parkinson's disease". Journal of Neurochemistry. 108 (2): 397–407. doi:10.1111/j.1471-4159.2008.05774.x. PMID 19012744.

[pmid8420138-5] Dostert P, Strolin Benedetti M, Della Vedova F, Allievi C, La Croix R, Dordain G, Vernay D, Durif F (1993). "Dopamine-derived tetrahydroisoquinolines and Parkinson's disease". Advances in Neurology. 60: 218–23. PMID 8420138.

[pmid9300617-6] Musshoff F, Daldrup T, Bonte W, Leitner A, Lesch OM (October 1997). "Salsolinol and norsalsolinol in human urine samples". Pharmacology Biochemistry and Behavior. 58 (2): 545–50. doi:10.1016/S0091-3057(97)00251-7. PMID 9300617. S2CID 76761.

[pmid14528920-7] Musshoff F, Lachenmeier DW, Kroener L, Schmidt P, Dettmeyer R, Madea B (July 2003). "Simultaneous gas chromatographic-mass spectrometric determination of dopamine, norsalsolinol and salsolinol enantiomers in brain samples of a large human collective". Cellular and Molecular Biology (Noisy-le-Grand, France). 49 (5): 837–49. PMID 14528920.

[pmid15026514-8] Scholz J, Klingemann I, Moser A (April 2004). "Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 75 (4): 634–6. doi:10.1136/jnnp.2003.010769. PMC 1739023. PMID 15026514.

[pmid15654290-9] Musshoff F, Lachenmeier DW, Schmidt P, Dettmeyer R, Madea B (January 2005). "Systematic regional study of dopamine, norsalsolinol, and (R/S)-salsolinol levels in human brain areas of alcoholics". Alcoholism: Clinical and Experimental Research. 29 (1): 46–52. doi:10.1097/01.ALC.0000150011.81102.C2. PMID 15654290.

[10] "(R)-Salsolinol, a product of ethanol metabolism, stereospecifically induces behavioral sensitization and leads to excessive alcohol intake. | PubFacts.com". www.pubfacts.com. Retrieved 2017-10-02.

Norsalsolinol information

and 24 Related for: Norsalsolinol information

Norsalsolinol

MDMA

Methamphetamine

Tetrahydroisoquinoline

MPTP

Salsolinol

Oxidopamine

C9H11NO2

Tubocurarine chloride

Fenpropathrin

Rotenone

Emetine

Cisatracurium besilate

Atracurium besilate

Deutetrabenazine

Drotaverine

List of adrenergic drugs

Anhalonidine

Salsoline

Moexipril

Anhalinine

Trifluoromethylaminoindane

Tariquidar

Dimethyltubocurarinium chloride